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Chitosan-γPGA–EGTA nanoparticlesThiswork examined the feasibility of preparing a pH-responsive nanoparticle (NP) system composed of chitosan
and poly(γ-glutamic acid) conjugated with ethylene glycol tetraacetic acid (γPGA–EGTA) for oral insulin deliv-
ery in diabetic rats during an oral glucose tolerance test (OGTT). OGTT has been used largely as amodel tomimic
the period that comprises and follows a meal, which is often associated with postprandial hyperglycemia. Based
on Förster resonance energy transfer (FRET), this work also demonstrated the ability of γPGA–EGTA to protect
insulin from an intestinal proteolytic attack in living rats, owing to its ability to deprive the environmental calci-
um. Additionally, EGTA-conjugated NPs were effective in disrupting the epithelial tight junctions, consequently
facilitating the paracellular permeation of insulin throughout the entire small intestine.Moreover, results of pos-
itron emission tomography and computer tomography demonstrated the effective absorption of the permeated
insulin into the systemic circulation as well as promotion of the glucose utilization in themyocardium, and skel-
etal muscles of the chest wall, forelimbs and hindlimbs, resulting in a signiﬁcant glucose-lowering effect. Above
results indicate that as-prepared EGTA-conjugated NPs are a promising oral insulin delivery system to control
postprandial hyperglycemia and thus may potentially prevent the related diabetic complications.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Blood glucose levels in diabetic patients often increase promptly
and signiﬁcantly after a meal, possibly related to the development
of diabetic complications [1]. As the most effective glucose-lowering
agent, insulin can stimulate glucose uptake in skeletal muscles, myo-
cardium, and other tissues in order to control glucose homeostasis
[2]. Although subcutaneous (SC) administration of insulin remains
the most prevalent means of treating diabetic patients, its patient
compliance is poor, owing to their phobia of needles and local pain
[3–5].ngineering, National Tsing Hua
74 2504.
ng).
Su) contributed equally to this
.V. Open access under CC BY license.Alternatively, oral delivery of insulin is a promising means of
improving compliance among diabetic patients. However, the bio-
availability of insulin via oral ingestion is limited, owing to its
presystematic degradation and the absorption barriers posed by the
intestinal epithelium [3]. To address these limitations, our recent
work developed a pH-responsive nanoparticle (NP) system compris-
ing chitosan (CS) and poly(γ-glutamic acid) conjugated with ethyl-
ene glycol tetraacetic acid (γPGA–EGTA) for oral insulin delivery [6].
According to those results, the CS/γPGA–EGTA NPs (EGTA-conjugated
NPs) could inhibit the proteolytic degradation of insulin and improve
its paracellular permeability in vitro, as well as enhance the oral bio-
availability of insulin in fasting diabetic rats.
As is well known, postprandial hyperglycemia is a more sensitive
indicator of diabetic control than fasting glucose levels [7]. The oral
glucose tolerance test (OGTT) has been used as a model to mimic the
postprandial state of hyperglycemia as well as provides information
on the glucose-lowering effect as a consequence of insulin action on
the glucose utilization [8].
We hypothesize that insulin absorbed into the systemic circula-
tion, as delivered by the EGTA-conjugated NPs orally, can effectively
514 E.-Y. Chuang et al. / Journal of Controlled Release 172 (2013) 513–522promote the glucose utilization and then control the postprandial hy-
perglycemia during OGTT in diabetic rats. The ability of γPGA–EGTA
to inhibit insulin from enzymatic degradation was also evaluated via
an in vivo imaging system (IVIS), based on the concept of Förster res-
onance energy transfer (FRET). Effects of the EGTA-conjugated NPs
on disrupting the ultra-structures of epithelial tight junctions (TJs)
and enhancing the intestinal absorption of insulin were visualized
directly in vivo by transmission electron microscopy (TEM) and con-
focal laser scanning microscopy (CLSM), respectively. Biodistribution
of the absorbed insulin and its subsequent stimulation of glucose
uptake were imaged noninvasively by using positron emission to-
mography (PET)/computer tomography (CT). Their pharmacokinetic
(PK) and pharmacodynamic (PD) proﬁles during OGTT were also
analyzed.
2. Materials and methods
2.1. Preparation and characterization of EGTA-conjugated NPs
The 85% deacetylated CS (MW 60 kDa) was purchased from Koyo
Chemical Co. Ltd. (Japan), whereas γPGA (MW100 kDa)was acquired
from Vedan Co. (Taichung, Taiwan). Insulin and EGTA were obtained
from Sigma-Aldrich (St. Louis, MO, USA). The γPGA–EGTA conjugate
was synthesized based on the procedure described in our previous
study [6]. Insulin-loaded EGTA-conjugated NPs were prepared using
an ionic-gelation method. Brieﬂy, bovine insulin (2 mg/mL, 0.5 mL)
was premixed with an aqueous CS solution (1.2 mg/mL, 4 mL, pH 6.0)
in the presence of sodium tripolyphosphate (TPP, 1 mg/mL, 0.5 mL) by
magnetic stirring at 4 °C for 15 min. Subsequently, the mixed solution
was added, via ﬂush mixing with a pipette tip, into an aqueous γPGA–
EGTA solution (4 mg/mL, 0.5 mL, pH 7.4) and then blended thoroughly
at room temperature to form the testNPs. Finally, the obtainedNPswere
collected via centrifugation at 8000 rpm for 50 min, resuspended in de-
ionized (DI)water, and freeze-driedwith trehalose (i.e., a cryoprotective
agent) for further use [9].
The particle size and zeta potential of the as-prepared NPs were
measured by dynamic light scattering (Zetasizer 3000HS, Malvern
Instruments Ltd., Worcestershire, UK). The loading efﬁciency and
loading content of insulin in NPs were determined by assaying the
amounts of free insulin in supernatants by using high-performance
liquid chromatography [6]. The drug loading efﬁciency (LE) and load-
ing content (LC) were calculated as shown below [5].
LE %ð Þ ¼ Total amount of insulin added free insulin
total amount of insulin added
 100%
LC %ð Þ ¼ Total amount of insulin added free insulin
weight of NPs
 100%
2.2. Detection of insulin degradation by FRET analyses
FRET involves the non-radiative transfer of energy from the excit-
ed state of a donor to the empty levels of an acceptor placed in close
proximity (b10 nm), and, subsequently, the conformational changes
of proteins can be probed using its efﬁciency [10]. To detect the deg-
radation of insulin (or its conformational changes) based on FRET, an
insulin derivative conjugating the ﬂuorescent cyanine 3 (Cy3) and cy-
anine 5 (Cy5) moieties (Cy3–insulin–Cy5) was prepared. Brieﬂy, equi-
molar N-hydroxy-succinimide-functionalized Cy3 and Cy5 (2.6 mg/mL,
0.1 mL, GE Healthcare, Little Chalfont, UK) were reacted with insulin
(10 mg/mL, 1 mL, 27.4 IU/mg) at pH 9.5 in an ice bath for 24 h [11].
The unconjugated Cy3 and Cy5 molecules were removed via dialysis
in distilled water at 4 °C for 3 days. Following dialysis, the obtained
Cy3–insulin–Cy5 was lyophilized for the subsequent in vitro and in
vivo degradation studies.In the in vitro study, the synthesized Cy3–insulin–Cy5 (1 mg) was
incubated with trypsin (4 mg) in a Krebs-Ringer buffer (KRB, 1 mL,
pH 7.4) containing CaCl2 (0.06 mg) with or without γPGA–EGTA
(40 mg) at 37 °C for 2 h [12]. Insulin is highly sensitive to trypsin,
which is a Ca2+-dependent enzyme present in the intestinal ﬂuid
and mucus layer [13]. Next, the degradation of Cy3–insulin–Cy5 was
monitored by FRET analyses, in which the donor (Cy3) was excited
at 535 nm and the emission spectra of the donor–acceptor were
recorded at all wavelengths simultaneously by using a ﬂuorescence
spectrometer (Horiba Jobin Yvon, Edison, NJ, USA).
The in vivo animal study was conducted in compliance with
the “Guide for the Care and Use of Laboratory Animals”, which was
prepared by the Institute of Laboratory Animal Resources, National
Research Council, and published by the National Academy Press in
1996, and approved by the Institutional Animal Care and Use Com-
mittee of National Tsing Hua University (protocol number 10046).
The enzymatic degradation of insulin was investigated in vivo using
an intestinal closed-loop method [14]. Brieﬂy, overnight-fasted rats
(Wistar, ~250 g, n = 5) were anesthetized via the intramuscular in-
jection of Zoletil® (50 mg/kg, Virbac Laboratories, Carros, France).
The abdominal cavity of animals was opened by a midline incision,
and the small intestine was exposed. A 5-cm segment of the duode-
num was then selected for producing a closed loop. The proximal
end of the intestinal loop was ﬁrst tied up, and the Cy3–insulin–Cy5
(2 mg/mL, 0.5 mL) in the absence or presence of γPGA–EGTA
(40 mg) was then introduced via a syringe. The distal end was subse-
quently ligated to form a closed loop.
Fluorescent signals of Cy3–insulin–Cy5 in the intestinal loop were
acquired by using an IVIS (Xenogen, Alameda, CA, USA). The test
animal was irradiated at a wavelength of 535 nm (the excitation
wavelength of Cy3) and imaged with an appropriate emission ﬁlter
(680 nm) to obtain Cy5 images. The ﬂuorescent intensities from re-
gions of interest were quantiﬁed using Living Image 3.1 software.
2.3. Ultra-structural examination of the permeability of epithelial TJs
The epithelial TJ permeability was observed directly by examining
the ultra-structural changes induced by the EGTA-conjugated NPs at
different segments of the small intestine by using TEM. In the work,
the loops created in the duodenum, jejunum and ileum were individ-
ually treated with the test NPs (2 mg/mL, 0.5 mL). Three hours later,
the rats were sacriﬁced; the intestinal loops were subsequently
dissected and washed three times with isotonic saline. Next, the dis-
sected loops were ﬁxed in 4% paraformaldehyde and washed with
s-Collidine buffer. To illustrate the paracellular permeability, the
ﬁxed loops were further incubated with 2% lanthanum, an electron-
dense tracer, for 2 h [15]. After rinsing in s-Collidine and phosphate
buffered saline (PBS), tissue samples were processed for TEM exami-
nation, as detailed previously [16].
2.4. Structural reorganization of TJs and intestinal absorption of insulin
The ﬂuorescein isothiocyanate-labeled insulin (FITC-insulin) was
synthesized [17] and then loaded in the EGTA-conjugated NPs. Next,
as-prepared ﬂuorescent NPs were introduced into the intestinal
loops created in rats (n = 6), as described above. At 2 h following
treatment, three of the studied rats were sacriﬁced, and their loop
segments were dissected to examine the corresponding structural re-
organization of TJs and intestinal absorption of insulin. Additionally,
to study the recovery of TJ structures after removal of test NPs, the
ligations of the intestinal loops created in the other three rats were
removed and then eluted with deionized (DI) water thoroughly.
Twenty-four hours later, rats were sacriﬁced, and their intestinal
loops were dissected.
The dissected intestinal loops were washed with PBS and then
ﬁxed in paraformaldehyde. Following ﬁxation, tissue samples were
515E.-Y. Chuang et al. / Journal of Controlled Release 172 (2013) 513–522embedded in parafﬁn and sectioned (5 μm in thickness). Non-speciﬁc
bindingwas blocked in 5%normal goat serum(Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) in PBS for 60 min at 37 °C. Test
samples were subsequently treated with primary antibodies (rabbit
anti ZO-1, Zymed Laboratories, San Francisco, CA, USA) at a 1:50
dilution for 60 min at 37 °C. After rinsing 3 times with PBS, tissue
samples were incubated with Alexa-Fluor-conjugated secondary an-
tibodies (Jackson ImmunoResearch Laboratories) with a 1:100 dilu-
tion. Samples were also counterstained with propidium iodide (PI,
Invitrogen, Carlsbad, CA, USA) to visualize the nuclei and observe
via an inverted CLSM (TCS SL, Leica, Germany).2.5. Toxicity of test NPs
Toxicity of the EGTA-conjugated NPs was evaluated in ICR mice
(25–30 g, National Laboratory Animal Center, Taipei, Taiwan). Ani-
mals were randomly divided into two groups. The experimental
group orally received a daily dose of empty NPs (100 mg/kg, n = 5
for each gender) for 14 days, while the other group without any treat-
ment was used as a control. Animals were fed with normal chow
and water ad libitum, followed by careful observation for the onset of
any signs of toxicity and monitoring for changes in body weight. The
mice were then sacriﬁced, along with their internal organs harvested
and examined. For sectional histology, intestine, liver and kidney
specimens were ﬁxed in 10% phosphate buffered formalin, embedded
in parafﬁn, cross sectioned at 5 μmand then stainedwith hematoxylin
and eosin (H&E) [18].0 min 30 min 60 min
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Fig. 1. a) FRET spectra of Cy3–insulin–Cy5 suspensions treated by trypsin with (w/) or witho
570 nm; (b) Cy5-emission images and (c) the intensities of Cy3–insulin–Cy5 suspensions pre
in vivo imaging system. *Statistical signiﬁcance at a level of P b 0.05.2.6. Biodistribution study during OGTT
Biodistribution of the insulin orally delivered by the EGTA-conjugated
NPs and the insulin-mediated glucose utilization were noninvasively
investigated in the streptozotocin-induced diabetic rats [19] during
OGTT by using PET/CT (n = 3). In the work, the diethylene triamine
pentaacetic acid (DTPA) conjugated insulin was ﬁrst synthesized to
immobilize gallium-68 (68Ga), a radioisotope suitable for PET imaging
[20]. Test NPs were then prepared using the obtained 68Ga-insulin, as
mentioned earlier.
To assess the insulin biodistribution administered to diabetic rats,
dynamic PET scans were acquired after oral ingestion of free-form
68Ga-insulin or 68Ga-insulin-loaded NPs (30 IU/kg). Three days later,
glucose utilization was assessed by orally administering 1 mCi/kg
of 18F-2-ﬂuoro-2-deoxy-D-glucose (18F-FDG) together with glucose
(0.5 g/kg) to the same diabetic rats at 2 h after oral ingestion of
free-form insulin or the insulin-loaded NPs (30 IU/kg), a model of
OGTT. Dynamic PET images were then obtained through a PET scan-
ner (Siemens Medical Solutions, Knoxville, TN, USA). The obtained
images were reconstructed using the 2D OSEM method (4 iterations
and 16 subsets) with attenuation corrections. After PET scanning,
whole-body CT images were acquired using NanoSPECT/CT (Bioscan,
Washington, DC, USA) with the intravenous Conray contrast enhance-
ment (Mallinckrodt Inc., Saint Louis, MO, USA) to more clearly illus-
trate the heart, great vessels, liver and kidneys. Image fusion of 3D
image-volume-rendering of 68Ga-insulin PET, 18F-FDG PET, and CT
scans was then performed via the image workstation and PMOD ver-
sion 3 (PMOD Technologies Ltd., Zurich, Switzerland).0
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Efﬁcacy and bioavailability of the insulin orally delivered by the
EGTA-conjugated NPs during OGTT were examined by randomly di-
viding diabetic rats into four groups (n = 6 for each studied group).
The following formulations were individually administered to the
overnight-fasted animals: DI water (oral, empty control), an enteric-
coated capsule containing free-form insulin powder (30 IU/kg) and
trehalose (oral), an enteric-coated capsule ﬁlled with the test NPs
containing 30 IU/kg insulin (oral), and a SC injection of free-form in-
sulin solution (5 IU/kg).
To mimic the postprandial state, an oral dose of glucose (1 g/kg)
was administered to the animals at 2 h after receiving insulin treat-
ment or DI water. Blood samples were collected from the tail vein,
and the blood glucose levels were measured by a glucose meter
(LifeScan Inc., Milpitas, CA, USA). Next, plasma insulin levels were
analyzed by centrifuging the blood samples (10,000 rpm for 15 min)
and then quantifying them by using a bovine insulin ELISA kit
(Mercodia AB, Uppsala, Sweden). The relative bioavailability (BAR) of
the absorbed insulin was calculated using the following formula [9]:
BAR ¼
AUC oralð Þ  Dose scð Þ
AUC scð Þ  Dose oralð Þ
 100%
where AUC denotes the total area under the plasma insulin concentra-
tion vs. time curve.Control
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Fig. 2. (a) TEM micrographs of different segments of the rat small intestine before (control)
(TJ, as denoted by the blue arrow) induced by test NPs was revealed by the permeation of la
centages of leaky TJs observed at different segments of the small intestine. *Statistical signi2.8. Statistical analysis
The groups were compared using the one-tailed Student's t-test
(SPSS, Chicago, Ill). All data were presented as a mean value with its
standard deviation indicated (mean ± SD). Differences were consid-
ered statistically signiﬁcant when the P values were less than 0.05.
3. Results and discussion
OGTT has been used largely as a model to mimic the period that
comprises and follows a meal, which is often associated with post-
prandial hyperglycemia [21]. Insulin can promote the glucose uptake
in the insulin-responsive tissues (e.g., skeletal and cardiac muscles),
ultimately lowering the postprandial hyperglycemia [22]. This work
analyzed the in vivo efﬁcacy of the EGTA-conjugated NPs in enhancing
the oral absorption of insulin and its subsequent stimulation of
glucose utilization by using noninvasive imaging approaches. Such
methods can substantially reduce the amount of animals required
and limit the inter-subject variability, as the same animals can be
imaged at multiple time points [23]. Additionally, image-based analy-
ses of live animal models in a time-resolved manner provide an
improved spatial and temporal understanding of dynamic biological
processes [24].
3.1. FRET analyses of insulin degradation
Trypsin is a Ca2+-dependent protease present in the small intes-
tine that can degrade insulin [13]. Chelating agents, such as EGTA,0
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517E.-Y. Chuang et al. / Journal of Controlled Release 172 (2013) 513–522can deprive the environmental Ca2+, thus limiting the enzymatic
activity of trypsin towards insulin [13]. To maintain the concentration
of the chelating agent in needed areas, EGTA was conjugated on
γPGA; the γPGA–EGTA conjugate was then used to form NPs with
CS for oral insulin delivery.
The ability of γPGA–EGTA to protect insulin from the proteolytic
attack was studied by synthesizing an insulin-derivative bearing ﬂuo-
rescent Cy3 and Cy5 molecules (Cy3–insulin–Cy5). The Cy3 and Cy5
moieties conjugated on Cy3–insulin–Cy5 constitute a donor–acceptor
pair that is appropriate for evaluating the molecular integrity of insu-
lin during degradation, based on their FRET efﬁciency.
Fig. 1a illustrates the FRET spectra of Cy3–insulin–Cy5 before
(control) and after degraded by trypsin in vitro with or without
γPGA–EGTA, which were normalized to the maximum Cy3 emission
peak (~570 nm). According to this ﬁgure, the group without γPGA–
EGTA (blue curve), had a signiﬁcantly greater decrease in the ﬂuores-
cence emission ratio of Cy5/Cy3 than that of the control group (green
curve), suggesting a severe proteolytic degradation of Cy3–insulin–
Cy5. Conversely, the degradation of Cy3–insulin–Cy5 was markedly
reduced in the group with γPGA–EGTA (red curve), owing to its abil-
ity to deprive the environmental Ca2+, thus inhibiting the trypsin
activity.
The loop created in the duodenum was used in the in vivo enzy-
matic degradation study. As is well known, the pancreas secretes var-
ious digestive enzymes, including trypsin, into the duodenum [25]. In
the absence of γPGA–EGTA, the ﬂuorescence intensity of Cy3–insulin–
Cy5 detected in the intestinal loop decreased signiﬁcantly with time
(P b 0.05, Fig. 1b and c), indicating the enzymatic cleavage of Cy3–
insulin–Cy5. In contrast, with γPGA–EGTA, changes in ﬂuorescence
intensity in the loop over time were limited, thus conﬁrming the pro-
tective effect of γPGA–EGTA against the intestinal proteases.ZO-1 Insulin Nuc
B
ef
or
e 
NP
 
Tr
ea
tm
en
t
m 
Af
te
r N
P 
Tr
ea
tm
en
t
Af
te
r N
P 
R
em
ov
al
20 µ
Fig. 3. Fluorescence images taken by a confocal microscope and their corresponding schema
and the absorption of insulin (blue color) before and after incubation with the insulin-load3.2. Characteristics of the EGTA-conjugated NPs
The as-prepared NPs had a mean particle size of 323.1 ± 76.9 nm
with a zeta potential of 38.7 ± 4.2 mV. Their insulin loading efﬁciency
and content were 77.4 ± 3.9% and 17.8 ± 2.4%, respectively (n = 6
batches). The test NPs were stable in a pH range of 2.0–7.0. Beyond
this range, the particles became unstable and disintegrated, suggesting
their pH-responsiveness [26]. Similar characteristics were found for the
test NPs containing FITC-insulin or 68Ga-insulin.
3.3. Ultra-structural examination of the permeability of epithelial TJs
In the intestinal pH environments (pH 6.4–7.4), the acidic groups
on EGTA are deprotonated [27], thus accelerating their association
kinetics of Ca2+. Owing to its chelating effects on Ca2+-dependent
adhesion molecules, EGTA can provoke the disruptions of epithelial
TJs [28]. As the apical-most member of the junctional complexes, TJs
create a primary barrier to the diffusion of macromolecules through
the paracellular route in the epithelium [29].
Disruptions of the epithelial TJs induced by the EGTA-conjugated
NPs, resulting in the paracellular permeability, were examined by
TEM using lanthanum as a tracer. Lanthanum, an electron-dense
rare-earth element, has been extensively used to study the perme-
ability of junctional barriers [30]. Intact epithelial TJs prevent lantha-
num from permeating into paracellular routes, whereas disrupted or
leaky epithelial TJs exhibit lanthanum staining in intercellular spaces
[31].
Fig. 2a reveals that before NP treatment (control), the intact epi-
thelial TJs appeared as highly electron-dense structures (as indicated
by the blue arrow). After exposure to the EGTA-conjugated NPs, lan-
thanum inﬁltrated the paracellular spaces (as denoted by the redInsulin
NucleiZO-1
Villus
lei Superposition Illustration
tic illustrations of rat intestinal villi, showing the change of ZO-1 protein (green color)
ed NPs; the images after removal of test NPs are also shown.
518 E.-Y. Chuang et al. / Journal of Controlled Release 172 (2013) 513–522arrow), indicating the opening of intercellular junctions, throughout
the entire small intestine. The percentages of lanthanum-containing
intercellular spaces (or TJ opening) observed in the duodenum, jejunum
and ileum segments were 87.6%, 85.3% and 84.0% (n = 30), respective-
ly. Above results suggest that the as-prepared EGTA-conjugated NPs
effectively disrupted TJs, thus facilitating the paracellular permeation
throughout the entire intestine.3.4. Structural reorganization of TJs and intestinal absorption of insulin
The cytoplasmic protein, zona occludens-1 (ZO-1), profoundly
impacts the structural and functional organization of TJs. Disruptions
of ZO-1 at TJs have been observed in response to bacterial toxins or
absorption enhancers, which correlates with enhanced paracellular
permeability [32]. In this work, the retrieved loop segments were
immunoﬂuorescently stained for ZO-1 proteins to examine their TJ
structural reorganization and its subsequent intestinal insulin absorp-
tion before and after NP treatment.
According to Fig. 3, before NP treatment (control), a honeycomb-
like distribution of ZO-1 proteins (green color) in association with
the cellular surface was seen (see the last column for illustration).
At 2 h after receiving the EGTA-conjugated NPs, ZO-1 proteins
disappeared, an indication of TJ disruptions. This observation may
be owing to the fact that Ca2+-depletion, caused by the EGTA chelat-
ing effect, stimulates ZO-1 trafﬁcking to an acidic endosome and,
eventually, to the lysosome for degradation [33].70
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Fig. 4. (a) Changes in body weight with time and (b) representative photomicrographs of th
and after treated with test NPs in a dose of 100 mg/kg per day for 14 days.It has been reported that mucoadhesive CS NPs can adhere to and
inﬁltrate the mucus layer in the small intestine [34]. After adhering to
and inﬁltrating the mucus layer, the NP carriers became unstable and
disintegrated owing to their pH sensitivity, subsequently releasing
their loaded insulin near the underlying epithelial cells [34]. It is
known that the pH environment at the epithelial surface is near neu-
tral [35,36]. The released insulinwas then absorbed into the lacteal side
of the villi (as denoted by the white arrows in Fig. 3) through the
disrupted TJs. After removal of the test NPs, the epithelial villi displayed
a pattern of ZO-1 that resembled the control group, suggesting the res-
toration of TJs through the synthesis of ZO-1, via the mRNA translation
[37].
3.5. In vivo toxicity study
The gastrointestinal (GI) tract is normally exposed to various po-
tentially detrimental substances, including chemical and bacterial
toxins [38]. As our EGTA-conjugated NPs are capable of enhancing
the paracellular permeability by opening the epithelial TJs (Fig. 2), it
is therefore crucial to study whether this incident could lead to toxic-
ity in vivo. In this work, animals were treated with a daily dose of
empty EGTA-conjugated NPs for 14 days; the animals without treat-
ment were used as a control group.
Both investigated groups had no apparent clinical symptoms such
as diarrhea, fever or other systemic symptoms throughout the study.
Over 14 days, body weights of the experimental groups (male and fe-
male) increased slightly in a manner similar to those of the control8 10 12 14
Control (Male)
Control (Female)
NPs (Male)
NPs (Female)
e (days)
(n = 5)
iver Kidney
e intestine, liver and kidney sections (H&E staining, magniﬁcation 200×) of mice before
519E.-Y. Chuang et al. / Journal of Controlled Release 172 (2013) 513–522groups; no gender-related difference was found (Fig. 4a). As is widely
recognized, the reduction in body-weight gain is a simple and sensi-
tive index of in vivo toxicity [39]. The speciﬁc tissue-level toxicological
study includes the inﬂammation (intestine), hepatotoxicity (liver),
and nephrotoxicity (kidney) responses [40]. Our histological assess-
ments found no noticeable tissue damages or toxic effects on organs
(Fig. 4b).
3.6. Biodistribution during OGTT
PET is a highly effective noninvasive technique formolecular imag-
ing in living animals [41]. Given its high sensitivity and high spatial–
temporal resolution, PET is particularly useful in analyzing the time
proﬁle of drug accumulation in speciﬁc tissues [41,42]. As a well-
known PET probe in clinical practice, 18F-FDG is a radiopharmaceutical
analog of glucose that can be taken up by metabolically active cells,
using facilitated transport similar to that used by glucose [43].
The biodistribution of oral ingestion of free-form 68Ga-insulin
was examined by PET; the obtained images were superimposed on
the CT scans of test animals for better anatomy localization (Fig. 5).
At 2 h following treatment, the coronal section of PET images from
retroperitoneum to abdomen revealed that the radioactivity of 68Ga-
insulin was present only along the GI tract. Despite the absorption of
18F-FDG into the systemic circulation and its presence in the kidneys
and urinary bladder, no apparent 18F-FDG utilization in the limbs
and cardiac muscles was detected. This observation is likely due to
the hypoinsulinemia in diabetic rats, resulting in the down-regulation
of the number of glucose transporters (Glut4) in these muscle cells
(Fig. 6), ultimately diminishing the transport capacity of 18F-FDG [44].
Conversely, the 68Ga-insulin delivered by the EGTA-conjugated NPs
was observed not only in the GI tract, but also in the heart, mediasti-
num, great vessels, kidneys and urinary bladder, which is indicative of
systemic absorption of 68Ga-insulin. The radioactivity of 18F-FDG was18
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Fig. 5. Biodistribution of 68Ga-insulin (in its free form or delivered by test NPs) and 18F-FDG
trations of 68Ga-insulin and 18F-FDG in different organs are shown in rainbow pseudo-colofound in the GI tract, kidneys and urinary bladder; additional radioac-
tivity uptakes were found in the myocardium, and skeletal muscles of
chest wall, forelimbs and hindlimbs, suggesting insulin-enhanced glu-
cose utilization in these tissues.
This work also attempted to enable real-time visual monitoring
and assessment of their biological processes by superimposing
the sequential 3D volume-rendering PET/CT images of 68Ga-insulin
(red color) and 18F-FDG (green color) onto the soft-tissue contrast-
volume-rendering CT images (gray color, Fig. 7 and Supplementary
Video). As shown, the radioactivities of 68Ga-insulin and 18F-FDG
(with an approximately 2-h time lag) propagated from the esophagus,
stomach through small intestine and, then, accumulated into the sys-
temic circulation after oral ingestion. In response to the stimulation of
the absorbed 68Ga-insulin, the 18F-FDG radioactivity uptakewas found
in the myocardium and skeletal muscles with time. Above results sug-
gest that the 68Ga-insulin delivered by the EGTA-conjugated NPs can
be effectively absorbed into the systemic circulation, thus enhancing
the 18F-FDG utilization in the insulin-responsive tissues. As is well
known, insulin stimulates glucose transport into muscle cells, where
it can be stored for future energy use, by enriching the concentration
of the glucose transporters (Glut4) at the surface of the cells (Fig. 6)
[45].
3.7. PK/PD proﬁles during OGTT
During OGTT, the SC injection of free-form insulin solution resulted
in a maximum plasma concentration at 1 h post administration (the
PK proﬁle, Fig. 8a), leading to a sharp decrease in blood glucose levels
(the PD proﬁle, Fig. 8b). Conversely, oral administration of DI water
or a capsule containing free-form insulin powder produced negligible
insulin absorption (Fig. 8a) and insigniﬁcant glucose-lowering effects
(P > 0.05, Fig. 8b). However, orally administering the capsule containing
the insulin-loaded EGTA-conjugated NPs revealed a maximum insulinAbdomenetroperitoneum
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by test NPs at time 0) and 18F-FDG (green color, ingested at 2 h post insulin intake) in various body compartments obtained at different time points.
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Fig. 6. Schematic diagrams illustrating the procedure of oral glucose tolerance test (OGTT) and the mechanism of test NPs in enhancing the oral absorption of insulin and its sub-
sequent stimulation of glucose utilization in muscle cells. The NPs facilitate paracellular permeability of insulin by disrupting the epithelial TJs; the absorbed insulin enriches the
number of glucose transporters at the plasma membrane of muscle cells, resulting in their increased utilization of glucose.
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521E.-Y. Chuang et al. / Journal of Controlled Release 172 (2013) 513–522concentration at 5 h after treatment (the blue line in Fig. 8a), resulting
in a signiﬁcant glucose-lowering effect (P b 0.05, Fig. 8b) due to the
insulin-mediated glucose utilization (Figs. 5 and 7); its AUC(0–10 h)
was 202.9 ± 32.5 μIU h/mL, and the corresponding BAR was 17.8 ±
1.3% (Table 1).4. Conclusions
In this work, a NP carrier system containing EGTAwas prepared for
oral insulin delivery in diabetic rats during OGTT to mimic the period
after a meal. Experimental results indicate that the EGTA-conjugated
NPs could enhance the oral absorption of insulin, thus ameliorate
postprandial hyperglycemia by facilitating the glucose utilization in
the insulin-responsive tissues. Adequately controlling postprandial
hyperglycemia helps to reduce the risk of diabetic complications.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jconrel.2013.05.006.Table 1
Pharmacokinetic parameters of insulin in diabetic rats following subcutaneous (SC) in-
jection of free-form insulin solution, oral administration of deionized (DI) water, oral
administration of a capsule containing free-form insulin powders or insulin-loaded
nanoparticles (NPs). Cmax: maximum plasma concentration; Tmax: time at which Cmax
is attained; AUC(0–10 h): area under the plasma concentration–time curve; BAR: relative
bioavailability (n = 6).
SC free-form
insulin solution
Oral DI
water
Oral free-form
insulin powders
Oral insulin-loaded
NPs
Dose (IU/kg) 5.0 0.0 30.0 30.0
Cmax (μIU/mL) 119.6 ± 3.8 N/A 1.1 ± 0.5 36.5 ± 15.4
Tmax (h) 1.0 N/A 5.0 5.0
AUC(0–10 h)
(μIU h/mL)
190.0 ± 27.1 N/A 5.8 ± 2.7 202.9 ± 32.5
BAR (%) 100 N/A 0.1 ± 0.3 17.8 ± 1.3Acknowledgments
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